Drugs / [18F]fluoro-2-deoxy-D-glucose
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01246869 | Mar 2013 → May 2014 | brain cancer | University of Utah | Terminated | No outcome recorded |
| Phase 1 | NCT00813566 | Nov 2010 → Feb 2015 | brain neoplasm, cancer | University of Utah | Completed | No outcome recorded |
| Phase 1 | NCT00707213 | Aug 2007 → Aug 2010 | cancer | University of Utah | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00708045 | May 2007 → Feb 2015 | cancer | University of Utah | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00588185 | Feb 2003 → Feb 2027 expected | prostate cancer | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]fluoro-2-deoxy-D-glucose | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00813566 ↗ |
| Known as | FDG | “[18F]fluoro-2-deoxy-D-glucose (FDG)” NCT00708045 ↗1“[18F]fluoro-2-deoxy-D-glucose (FDG)” NCT01246869 ↗ |
| Modality | Diagnostic / imaging agent | “FDG-PET/CT scan-The scans that will be done with a radioactive sugar” NCT00707213 ↗ |